AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Phase 3 Results and Biomarker Nuances
Karim Fizazi outlines phase 3 findings, differences between IHC and NGS-defined PTEN loss outcomes.
Play episode from 36:17
Transcript
